{"filing":{"accession_number":"0001213900-26-060830","cik":"0002108121","ticker":null,"company_name":"Ionetix Corp / DE /","form":"8-K","filing_date":"2026-05-26","report_date":null,"primary_document":"ea0292072-8k_ionetix.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2108121/000121390026060830/ea0292072-8k_ionetix.htm"},"events":[{"id":9058,"run_id":7953,"accession_number":"0001213900-26-060830","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"The Company announced FDA approval of its ANDA for Gallium Ga-68 gozetotide (PSMA-11), a significant regulatory milestone for a pharmaceutical company. While this is a material event affecting investor assessment of the registrant's product pipeline and commercial prospects, it does not fit neatly into the predefined taxonomy categories (not an earnings release, M\u0026A activity, impairment, or other specific event types). This regulatory approval is best classified as \"other_material\" given its clear materiality to a pharmaceutical company's business prospects.","company_name":"Ionetix Corp / DE /","ticker":null,"filing_date":"2026-05-26","form":"8-K","submitted_at":null,"items":[{"id":1545,"accession_number":"0001213900-26-060830","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The Company announced FDA approval of its ANDA for Gallium Ga-68 gozetotide (PSMA-11), a significant regulatory milestone for a pharmaceutical company. While this is a material event affecting investor assessment of the registrant's product pipeline and commercial prospects, it does not fit neatly into the predefined taxonomy categories (not an earnings release, M\u0026A activity, impairment, or other specific event types). This regulatory approval is best classified as \"other_material\" given its clear materiality to a pharmaceutical company's business prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:13:44.336419+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1545,"accession_number":"0001213900-26-060830","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The Company announced FDA approval of its ANDA for Gallium Ga-68 gozetotide (PSMA-11), a significant regulatory milestone for a pharmaceutical company. While this is a material event affecting investor assessment of the registrant's product pipeline and commercial prospects, it does not fit neatly into the predefined taxonomy categories (not an earnings release, M\u0026A activity, impairment, or other specific event types). This regulatory approval is best classified as \"other_material\" given its clear materiality to a pharmaceutical company's business prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:13:44.336419+00:00","company_name":"Ionetix Corp / DE /","ticker":null,"filing_date":"2026-05-26"}]}